

COVID-19 VACCINATION SCHEDULE AND DOSING


AGES 6 MONTHS TO <5 YEARS

UNVACCINATED

dose/injection volume

Moderna Bivalent:
(Do NOT dilute before use)
Dark Blue Cap (gray label)

Pfizer Bivalent:
(dilute before use)
Maroon Cap




PREVIOUSLY VACCINATED

dose/injection volume

☐ **Previously Received COVID-19 Vaccines**

Moderna Bivalent:
(Do NOT dilute before use)
Dark Blue Cap (gray label)
Dark Pink Cap (yellow label)

Pfizer Bivalent:
(dilute before use)
Maroon Cap



†FDA [EUA](#) requires that children who transition from age 4 to 5 years during the Pfizer-BioNTech vaccination series receive the 0.2 mL/3 µg dosage (maroon cap and label with a maroon border) for all doses.

See the [CDC's Guidance](#) for latest updates and information on who is considered moderately or severely immunocompromised.

COVID-19 VACCINATION SCHEDULE AND DOSING


AGES 6 MONTHS TO <5 YEARS - MODERATELY TO SEVERELY IMMUNOCOMPROMISED

UNVACCINATED

dose/injection volume

Moderna Bivalent:
(Do NOT dilute before use)
Dark Blue Cap (gray label)

Pfizer Bivalent:
(dilute before use)
Maroon Cap




PREVIOUSLY VACCINATED

dose/injection volume

Previously Received COVID-19 Vaccines

Moderna Bivalent:
(Do NOT dilute before use)
Dark Blue Cap (gray label)
Dark Pink Cap (yellow label)

Pfizer Bivalent:
(dilute before use)
Maroon Cap



Immunocompromised Guidance

For Pfizer, there is no additional guidance for immunocompromised at this time.

Certain kinds of immunocompromise refers to individuals who have undergone solid organ transplantation, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise.

Additional Considerations

An 8-week interval between the first and second doses of Moderna and Pfizer-BioNTech COVID-19 vaccines might be optimal for some people ages 6 months–64 years, especially for males ages 12–39 years, as it might reduce the small risk of myocarditis and pericarditis associated with these vaccines.

See the [CDC's Guidance](#) for latest updates and information on who is considered moderately or severely immunocompromised.

COVID-19 VACCINATION SCHEDULE AND DOSING

AGES 5 TO <6 YEARS

UNVACCINATED

dose/injection volume

Moderna Bivalent:


(Do NOT dilute before use)

Dark Blue Cap (gray label)

Pfizer Bivalent:

(dilute before use)

Orange Cap



Immunocompromised Guidance for Pfizer-BioNTech

For individuals with certain kinds of immunocompromise 5 years of age and older, a single additional age-appropriate dose of Pfizer-BioNTech COVID-19 Vaccine, Bivalent may be administered at least 2 months following the initial dose of a bivalent COVID-19 vaccine; additional age-appropriate doses of Pfizer-BioNTech COVID-19 Vaccine, Bivalent may be administered at the discretion of the healthcare provider, taking into consideration the individual's clinical circumstances.

Immunocompromised Guidance for Moderna

For individuals with certain kinds of immunocompromise 6 months through 5 years of age who have received two 0.25 mL doses (Moderna COVID-19 Vaccine or Moderna COVID-19 Vaccine, Bivalent), an additional 0.25 mL dose of Moderna COVID-19 Vaccine, Bivalent (vial with a dark blue cap and a label with a gray border) may be administered at least 1 month following the most recent dose; additional doses of Moderna COVID-19 Vaccine, Bivalent may be administered at the discretion of the healthcare provider, taking into consideration the individual's clinical circumstances.

Additional Considerations

An 8-week interval between the first and second doses of Moderna and Pfizer-BioNTech COVID-19 vaccines might be optimal for some people ages 6 months–64 years, especially for males ages 12–39 years, as it might reduce the small risk of myocarditis and pericarditis associated with these vaccines.

See the [CDC's Guidance](#) for latest updates and information on who is considered moderately or severely immunocompromised.

COVID-19 VACCINATION SCHEDULE AND DOSING

AGES 6 TO <12 YEARS

UNVACCINATED

dose/injection volume

Moderna Bivalent:


(Do NOT dilute before use)

Dark Blue Cap (gray label)

Pfizer Bivalent:

(dilute before use)

Orange Cap



PREVIOUSLY VACCINATED

dose/injection volume

☐ Previously Received
COVID-19 Vaccines

Moderna Bivalent:

(Do NOT dilute before use)


Dark Blue Cap (gray label)

Dark Pink Cap (yellow label)

Pfizer Bivalent:

(dilute before use)

Orange Cap



Immunocompromised Guidance for Pfizer-BioNTech

For individuals with certain kinds of immunocompromise 5 years of age and older, a single additional age-appropriate dose of Pfizer-BioNTech COVID-19 Vaccine, Bivalent may be administered at least 2 months following the initial dose of a bivalent COVID-19 vaccine; additional age-appropriate doses of Pfizer-BioNTech COVID-19 Vaccine, Bivalent may be administered at the discretion of the healthcare provider, taking into consideration the individual's clinical circumstances.

Immunocompromised Guidance for Moderna

For individuals with certain kinds of immunocompromise 6 years of age and older, a single additional age-appropriate dose of Moderna COVID-19 Vaccine, Bivalent may be administered at least 2 months following the initial dose of a bivalent COVID-19 vaccine; additional age-appropriate doses of Moderna COVID-19 Vaccine, Bivalent may be administered at the discretion of the healthcare provider, taking into consideration the individual's clinical circumstances.

Additional Considerations

An 8-week interval between the first and second doses of Moderna and Pfizer-BioNTech COVID-19 vaccines might be optimal for some people ages 6 months–64 years, especially for males ages 12–39 years, as it might reduce the small risk of myocarditis and pericarditis associated with these vaccines.

See the [CDC's Guidance](#) for latest updates and information on who is considered moderately or severely immunocompromised.

COVID-19 VACCINATION SCHEDULE AND DOSING

AGES 12 YEARS AND OLDER

UNVACCINATED

dose/injection volume

Moderna Bivalent:


(Do NOT dilute before use)

Dark Blue Cap (gray label)

Pfizer Bivalent:

(Do NOT dilute before use)

Gray Cap



PREVIOUSLY VACCINATED

dose/injection volume

☐ **Previously Received COVID-19 Vaccines**

Moderna Bivalent:


(Do NOT dilute before use)

Dark Blue Cap (gray label)

Pfizer Bivalent:

(Do NOT dilute before use)

Gray Cap



ADDITIONAL DOSES

dose/injection volume

☐ **Previously Received COVID-19 Vaccines**

Moderna Bivalent:

(Do NOT dilute before use)

Dark Blue Cap (gray label)

Pfizer Bivalent:

(Do NOT dilute before use)

Gray Cap

65 YEARS AND OLDER

People ages 65 years and older have the option to receive 1 additional bivalent mRNA vaccine dose at least 4 months after the first dose of a bivalent mRNA vaccine.



Immunocompromised Guidance for Pfizer-BioNTech

For individuals with certain kinds of immunocompromise 5 years of age and older, a single additional age-appropriate dose of Pfizer-BioNTech COVID-19 Vaccine, Bivalent may be administered at least 2 months following the initial dose of a bivalent COVID-19 vaccine; additional age-appropriate doses of Pfizer-BioNTech COVID-19 Vaccine, Bivalent may be administered at the discretion of the healthcare provider, taking into consideration the individual's clinical circumstances.

Immunocompromised Guidance for Moderna

For individuals with certain kinds of immunocompromise 6 years of age and older, a single additional age-appropriate dose of Moderna COVID-19 Vaccine, Bivalent may be administered at least 2 months following the initial dose of a bivalent COVID-19 vaccine; additional age-appropriate doses of Moderna COVID-19 Vaccine, Bivalent may be administered at the discretion of the healthcare provider, taking into consideration the individual's clinical circumstances.

Additional Considerations

An 8-week interval between the first and second doses of Moderna and Pfizer-BioNTech COVID-19 vaccines might be optimal for some people ages 6 months–64 years, especially for males ages 12–39 years, as it might reduce the small risk of myocarditis and pericarditis associated with these vaccines.

See the [CDC's Guidance](#) for latest updates and information on who is considered moderately or severely immunocompromised.